|
1
|
Bagan J, Sarrion G and Jimenez Y: Oral
cancer: Cral precancer and cancer and preventive measures. Clinical
Oral investigations. 5:207–213. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reichart PA: Identification of risk groups
for oral precancer and cancer and preventive measures. Clin Oral
Investig. 5:207–213. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Perez-Sayans M, Somoza-Martin JM,
Barros-Angueira F, Reboiras-Lopez MD, Gandara Rey JM and
Garcia-Garcia A: Genetic and molecular alterations associated with
oral squamous cell cancer (Review). Oncol Rep. 22:1277–1282. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sasahira T, Kirita T and Kuniyasu H:
Update of molecular pathobiology in oral cancer: A review. Int J
Clin Oncol. 19:431–436. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ost P, Bossi A, Decaestecker K, De
Meerleer G, Giannarini G, Karnes RJ, Roach M III and Briganti A:
Metastasis-directed therapy of regional and distant recurrences
after curative treatment of prostate cancer: A systematic review of
the literature. Eur Urol. 67:852–863. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sannam Khan R, Khurshid Z, Akhbar S and
Faraz Moin S: Advances of Salivary Proteomics in Oral Squamous Cell
Carcinoma (OSCC) Detection: An Update. Proteomes. 4(piii): E412016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gerdes J, Lemke H, Baisch H, Wacker HH,
Schwab U and Stein H: Cell cycle analysis of a cell
proliferation-associated human nuclear antigen defined by the
monoclonal antibody Ki-67. J Immunol. 133:1710–1715.
1984.PubMed/NCBI
|
|
8
|
Li LT, Jiang G, Chen Q and Zheng JN: Ki67
is a promising molecular target in the diagnosis of cancer
(review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Antonarakis ES, Keizman D, Zhang Z, Gurel
B, Lotan TL, Hicks JL, Fedor HL, Carducci MA, De Marzo AM and
Eisenberger MA: An immunohistochemical signature comprising PTEN,
MYC, and Ki67 predicts progression in prostate cancer patients
receiving adjuvant docetaxel after prostatectomy. Cancer.
118:6063–6071. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim J, Han W, Jung SY, Park YH, Moon HG,
Ahn SK, Lee JW, Kim MK, Kim JJ, Lee ES, et al: The Value of Ki67 in
Very Young Women with hormone receptor-positive breast cancer:
Retrospective Analysis of 9,321 Korean Women. Ann Surg Oncol.
22:3481–3488. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Melling N, Kowitz CM, Simon R, Bokemeyer
C, Terracciano L, Sauter G, Izbicki JR and Marx AH: High Ki67
expression is an independent good prognostic marker in colorectal
cancer. J Clin Pathol. 69:209–214. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pascale M, Aversa C, Barbazza R, Marongiu
B, Siracusano S, Stoffel F, Sulfaro S, Roggero E, Bonin S and
Stanta G: The proliferation marker Ki67, but not neuroendocrine
expression, is an independent factor in the prediction of prognosis
of primary prostate cancer patients. Radiol Oncol. 50:313–320.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou Y, Li Y, Zheng J, Liu K and Zhang H:
Detecting of gastric cancer by Bcl-2 and Ki67. Int J Clin Exp
Pathol. 8:7287–7290. 2015.PubMed/NCBI
|
|
14
|
Lindsay CR, Le Moulec S, Billiot F, Loriot
Y, Ngo-Camus M, Vielh P, Fizazi K, Massard C and Farace F: Vimentin
and Ki67 expression in circulating tumour cells derived from
castrate-resistant prostate cancer. BMC Cancer. 16:1682016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Panzuto F, Cicchese N, Partelli S,
Rinzivillo M, Capurso G, Merola E, Manzoni M, Pucci E, Iannicelli
E, Pilozzi E, et al: Impact of Ki67 re-assessment at time of
disease progression in patients with pancreatic neuroendocrine
neoplasms. PLoS One. 12:e01794452017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu M, Lawson G, Delos M, Jamart J, Ide C,
Coche E, Weynand B, Desuter G, Hamoir M, Remacle M and Marbaix E:
Predictive value of the fraction of cancer cells immunolabeled for
proliferating cell nuclear antigen or Ki67 in biopsies of head and
neck carcinomas to identify lymph node metastasis: Comparison with
clinical and radiologic examinations. Head Neck. 25:280–288. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Keohane SG, Proby CM, Newlands C, Motley
RJ, Nasr I, Mohd Mustapa MF and Slater DN: The new 8th edition of
TNM staging and its implications for skin cancer: a review by the
British Association of Dermatologists and the Royal College of
Pathologists, United Kingdom. Br J Dermatol. 2018.(Epub ahead of
print). View Article : Google Scholar
|
|
18
|
Heerema MG, Melchers LJ, Roodenburg JL,
Schuuring E, de Bock GH and van der Vegt B: Reproducibility and
prognostic value of pattern of invasion scoring in low-stage oral
squamous cell carcinoma. Histopathology. 68:388–397. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kuperman DI, Auethavekiat V, Adkins DR,
Nussenbaum B, Collins S, Boonchalermvichian C, Trinkaus K, Chen L
and Morgensztern D: Squamous cell cancer of the head and neck with
distant metastasis at presentation. Head Neck. 33:714–718. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Towle R, Truong D and Garnis C: Epigenetic
mediated silencing of EYA4 contributes to tumorigenesis in oral
dysplastic cells. Genes Chromosomes Cancer. 55:568–576. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Noguti J, De Moura CF, De Jesus GP, Da
Silva VH, Hossaka TA, Oshima CT and Ribeiro DA: Metastasis from
oral cancer: An overview. Cancer Genomics Proteomics. 9:329–335.
2012.PubMed/NCBI
|
|
23
|
Yurakh AO, Ramos D, Calabuig-Farinas S,
López-Guerrero JA, Rubio J, Solsona E, Romanenko AM, Vozianov AF,
Pellin A and Llombart-Bosch A: Molecular and immunohistochemical
analysis of the prognostic value of cell-cycle regulators in
urothelial neoplasms of the bladder. Eur Urol. 50:506–515. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brown DC and Gatter KC: Ki67 protein: The
immaculate deception? Histopathology. 40:2–11. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu TT, Chen JH, Lee YH and Huang JK: The
role of bcl-2, p53, and ki-67 index in predicting tumor recurrence
for low grade superficial transitional cell bladder carcinoma. J
Urol. 163:758–760. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li H, Han X, Liu Y, Liu G and Dong G: Ki67
as a predictor of poor prognosis in patients with triple-negative
breast cancer. Oncol Lett. 9:149–152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li W, Zhang G, Wang HL and Wang L:
Analysis of expression of cyclin E, p27kip1 and Ki67 protein in
colorectal cancer tissues and its value for diagnosis, treatment
and prognosis of disease. Eur Rev Med Pharmacol Sci. 20:4874–4879.
2016.PubMed/NCBI
|
